Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 13

Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients

Authors Wu X, Xu QJ, Chen PZ, Yu CB, Ye LF, Li T

Received 7 January 2020

Accepted for publication 13 April 2020

Published 4 June 2020 Volume 2020:13 Pages 181—188

DOI https://doi.org/10.2147/PGPM.S245086

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Martin H Bluth


Xiang Wu,1,2 Qing-Jiang Xu,1,2 Ping-Zhou Chen,1,2 Chen-Bo Yu,1,2 Lie-Fu Ye,1,2 Tao Li1,2

1Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, People’s Republic of China; 2Department of Urology, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of China

Correspondence: Tao Li Tel +86 13705078075
Email 1565175152@qq.com

Purpose: The purpose of this study was to investigate the association between single nucleotide polymorphisms (SNPs) of CYP17A1, CYB5A and the efficacy of abiraterone acetate treatment in patients with castration-resistant prostate cancer (CRPC).
Patients and Methods: Data were collected from 58 CRPC patients who had been treated with abiraterone acetate/prednisone (AA/P). The SNPs rs743572 and rs10883783 on CYP17A1 and SNPs rs1790834 and rs1790858 on CYB5A were assayed, and their relationship with prostate-specific antigen (PSA) response in patients after AA/P treatment, overall survival (OS) and progression-free survival (PFS) were analyzed by logistic regression, Cox regression, Kaplan–Meier and Log rank analyses.
Results: The SNP rs1790834 on CYB5A showed significant association with PSA response in CRPC patients treated with AA/P (P < 0.05), but rs743572, rs10883783 and rs1790858 did not. The rs1790834 variant significantly decreased both PFS and OS (P < 0.05).
Conclusion: The CYB5A rs790834 genotype is a novel SNP related to CRPC and may be used as a biomarker for CRPC treatment.

Keywords: abiraterone, androgens, castration-resistant prostate cancer, CYP17A1, CYB5A

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]